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Introduction 
In spite of advances in our knowledge to use coro- 
nary stents, there are still limitations to general appli- 
cability of the technique. Mechanical stiffness and 
thrombogenicity necessitating multidrug anticoagula- 
tion therapy are the most important problems. ',* 
Therefore, further research to improve the currently 
available devices is needed. At the present time, there 
is no consensus regarding the optimal stent design, 
or what surface should be used to achieve suitable 
properties with regard to prevention of thrombus for- 
mation and reactive vessel wall proliferation. 
The Benestent I trial, a multicenter randomized 
study comparing the safety and efficacy of primary 
Palmaz-Schatz stent implantation versus percutaneous 
transluminal coronary angioplasty (PTCA) in patients 
with stable angina pectoris and a single de novo lesion 
in a native coronary artery, has very recently been 
completed.3 This study demonstrated that event-free 
survival was higher in patients who received a stent 
compared to patients treated with PTCA (67% vs 55%) 
at 6-month follow-up. This was largely due to a reduc- 
tion of repeat revascularization in patients treated with 
a stent, caused mainly by a significantly lower resteno- 
sis rate in the stented group (22% vs 32%). However, 
the incidence of vascular complications (bleeding epi- 
sodes or pseudoaneurysm formation at the puncture 
?See Appendix. 
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site) and subacute coronary thrombosis was increased 
after stenting, reflecting the difficult balance between 
the thrombogenicity of the stent and the need for an 
intensive anticoagulation regimen. 
In order to further improve the clinical results of 
coronary stenting, we have directed our attention to 
coating the stent with material that would minimize 
the risk of abrupt stent closure and, thereby, allow 
reduction of anticoagulation therapy. To that purpose, 
a heparin-coated stent has been developed and tested 
in an animal model. In the following, a short descrip- 
tion will be given of the principles of the heparin coat- 
ing. Furthermore, the result of the animal studies will 
be summarized. Finally, the design of the pilot phase 
of the Benestent I1 study, an open, noncontrolled regis- 
try using a heparin-coated stent, will be outlined. 
Principles of Heparin Coating 
Blood compatibility is a critical requirement for in- 
travascular devices, since contact of blood with a for- 
eign surface will commonly result in deposition and 
activation of plasma proteins, platelets, and other cel- 
lular elements, leading to thrombus formation. During 
decades, there has been intensive research in the area 
of blood-compatible materials for noncoronary pur- 
p o s e ~ . ~  Instead of introducing a foreign material di- 
rectly into a blood vessel, material surface modifica- 
tions with improved properties with regard to blood 
and tissue compatibility appear to be a viable ap- 
proach. It has been shown that heparin-like molecules 
with anticoagulant activity are synthesized on the lu- 
minal surface of endothelial Indeed, the endo- 
thelium plays an important part in the inactivation of 
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thrombin and pohsibly also other coagulation factors. 
Not unexpectedly. therefore. heparin has been one of 
the inoxt extensively explored wbstances for adsorp- 
tion or binding to hiomaterial surfaces. Heparin-coated 
surfaces haw been ebaluatrd i n  various types of de- 
\.ices where thromboresixtance might be of particular 
clinical ~ ~ l u e .  e.g.. arterio\,enous shunts. catheters. ar- 
terial filters, oxygenators, cardiopulmonary bypass 
circuits. and vascular endoprostheses.'-" 
The principal anticoagulant mechanism of heparin 
is mediated by its interaction with antithrombin 111. 
This complex accelerates the inactivation of thrombin 
and other coagulation factors. I t  has been shown that 
the active site of heparin contains a specific carbohy- 
Figure 1. Sclieiiidic illumxiuii of method\ tor hrparinizcition of wrfnceh. Note that the active 
ciirhoh! dr.itr \t'qurnce of heparin ha \  the mht tq in i : i l  onentation for tnteriic'tioii with components 
<)t the hloiid, \\ hei-r. the iiiolecule\ are end a t t achd  and perpendicular to the surt'ace. Large symbols: 
mtithronihin I l l :  rinall \! mbol\- thrombin. tPerini\\icin iroin Carineda AB. Stockholm. Sheden. 1 
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Table 1. Methods for Heparin-Coating of Biomaterials 
Physically -Adsorbed into matric coatingz0," 
Ionically bonded -Benzalkonium vinyl alcohol'5 - I 8  
Covalent coupled -Mid-point attached alb~min-heparin~~; 
immobilized heparin block c o p ~ l y m e r ' ~ . ~ ~  
end-point attached heparinz6 
drate sequence. '*-I4 Obviously, when the heparin mol- 
ecule is modified in the process of surface coating, it 
is essential that the active sequence responsible for 
anticoagulation remains unaltered. 
There are various methods of binding heparin to a 
surface (Table 1). The simplest solution is adsorbing 
a heparin solution to the biomaterial ~ u r f a c e . ' ~ - ~ ~ * ~ ~  A 
problem with this type of heparin coating is the lack 
of control of the rate of release. The heparin molecule 
contains a large number of negatively charged groups, 
and may, therefore, be ionically or electrostatically 
bound to surfaces with positive charges (Fig. lA).'5-'8 
Heparin may also be covalently bonded, but this re- 
quires the development of specific chemistry between 
the heparin and the surface.--- 
Covalently Bonded Heparin. The aim of immobi- 
lization of heparin is to achieve endothelium-like 
thromboresistant properties of the surface. There is no 
general method available for heparin binding on all 
types of material used in medical devices. Since hepa- 
rin is a highly charged and hydrophilic polymer, the 
binding has to be prepared by pretreatment of the sur- 
face to be coated with reactive groups (' 'functionaliz- 
ing"). Obviously, this procedure will be more compli- 
cated if the device is composed of several materials 
that differ in chemical properties and surface charac- 
teristics. This problem does not play a role in the coat- 
ing of current metallic stents. 
9' 26.35 
In the early development of heparin coatings, a re- 
duction in heparin activity was frequently observed 
when the molecules were covalently attached to the 
surface, probably due to alteration of the active carbo- 
hydrate sequence during the linking proce~s .~ '  This 
problem was circumvented when heparin could be 
coupled by end point attachment (Fig. 1B).26.28 The 
first step in this procedure was partial degradation of 
heparin with nitrous acid, creating reactive aldehyde 
groups in the reducing terminal residues. It was shown 
by Larm et a1.26 in 1983 that heparin fragments could 
be immobilized by end point attachment on materials 
coated with polyethylenimine. The aldehyde groups 
were subsequently coupled to the aminated surface by 
reductive amination (Fig. 2 ) .  By this method, the ac- 
tive carbohydrate sequence of the heparin molecule 
can be preserved functionally intact throughout the 
coupling reaction. 
BENESTENT I1 
Vol. 7, No. 6, 1994 Journal of Interventional Cardiology 
1 NOQ 
NH2 
I 
NaBH3CN 
1 
CH20S03' 
NH 
Figure 2. Endpoint attachment by covalent coupling of partially 
nitrous acid degraded heparin to aminated surfaces. (Permission 
from Hoffman J, Larm 0, Scholander E. A new method for covalent 
coupling of heparin and other glycosaminoglycans to substances 
containing pnmary amino groups. Carbohydr Res 1983;117: 
328-33 1 .) 
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In addition to being compatible with the plasma co- 
agulation system. a thromboresistant surface should 
not promote adhesion and activation of platelets and 
leukocytes. Since heparin has been reported to induce 
platelet activation.'" this consequence might be ex- 
pected with surface immobilized heparin as well. 
However, it has been shown that in comparison to 
uncoated material, the surface with end point attached 
heparin on a high molecular weight polyamine stabi- 
lized with glutaraldehyde. was highly compatible with 
platelets as well as granulocytes and macro- 
phages.30-7' 
The principle of perpendicularly oriented. end at- 
tached. covalently bound and immobilized heparin 
molecules on a polymer surface (Carmeda Bioactive 
Surface. Carmeda AB. Stockholm) was considered the 
best candidate for coating of coronary stents. Pilot in 
vitro studies performed with stents coated with this 
surface demonstrated that the mounting on the balloon 
catheters and subsequent expansion of the stents did 
not affect the heparin activity. In contrast, sterilization 
with heat or ethylene oxide reduced the heparin activ- 
ity considerably (5070-708 loss). Consequently, for 
initial studies, the stents were coated under aseptic 
conditions or with higher concentrations of heparin 
to compensate for the loss of heparin activity during 
ethylene oxide sterilization. 
Results from Animal Experiments 
Palmaz Schatz"' htents were implanted in  four 
groups of nonatherosclerotic pigs ( n  = 3 5 ) .  Using the 
diameter of the guiding catheter as a reference, a seg- 
ment with a diameter of 2.5-3.5 mm was selected in 
the left anterior descending coronary artery using on- 
line quantitative coronary arteriography." Thereafter. 
either a heparin-coated or a conventional uncoated 
stent ( in  alternate order) was positioned at the site pre- 
selected for implantation.3' Postprocedure, 15 animals 
did not receive antithrombotic prophylaxis, whereas 
the remaining 20 pigs were administered 300-mg as- 
pirin orally starting the day before implantation. and 
this treatment was continued during the 28 days of 
After 3 weeks. coronary angiography was per- 
formed on all surviving animals using the same projec- 
tion as during implantation. Thereafter, the thorax was 
opened by a mid-sternal split, and a lethal dose of 
sodium pentobarbital was injected intravenously im- 
follow-up . 
mediately followed by cross-clamping of the ascend- 
ing aorta. The heart was excised after pressure infusion 
(120 mmHg) of 500 cc of saline followed by 500 cc 
of buffered formaldehyde and the coronary arteries 
were dissected from the epicardial surface. The stented 
and adjacent segments were then placed in 4% formal- 
dehyde in phosphate buffer for at least 48 hours in 
preparation for microscopy. After fixation, the stented 
segments were processed for light microscopical ex- 
amination. Hematoxilin-azaphloxin was used as a rou- 
tine stain while resorcin-fuchsin was used as an elastic 
stain. 
Results. In the IS animals without aspirin treatment, 
the thrombotic occlusion rate within 48 hours was 
33%. There were no differences in patency observed 
between the coated and the conventional stents. In the 
animals receiving aspirin there were four stent occlu- 
sions in the control group (40%), but none in the group 
with coated stents (P < 0.05). 
In conclusion, the demonstration of thromboresis- 
tance of heparin-coated stents in aspirin treated pigs 
was considered encouraging and created the basis for 
the subsequent phase of stent implantation in humans. 
Benestent I1 Trial-Pilot Phase 
The Benestent I1 study is an open, multicenter, non- 
randomized, prospective registry specifically designed 
to evaluate the safety of elective implantation of a hep- 
arin-coated Palmaz Schatz"' stent in patients with an- 
gina pectoris and a single de novo lesion in a native 
coronary artery (similar patient population as in 
Benestent I study). The primary objective of im- 
planting heparin-coated coronary stents in humans is 
to determine the incidence of acute and subacute 
thrombotic stent occlusion and the incidence. location, 
and severity of vascular and bleeding complications 
during hospital stay and within 30 days. Furthermore, 
the occurrence of all cardiac and noncardiac events 
during the same period (death. myocardial infarction, 
repeat revascularization procedures) will be assessed. 
Evaluating the efficacy of the procedure (symptom- 
and event-free survival at 6 months: freedom from 
death, myocardial infarction, or repeat interventions) 
and monitoring changes in stenosis geometry immedi- 
ately after stent implantation and at 6 months as as- 
sessed by quantitative coronary angiography will be 
secondary objectives. 
The design of the current trial is to implant heparin- 
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coated stents in a stepped-care approach. The study 
consists of three phases in which a total of 1.50 patients 
will be treated with a single type of stent (50 patients 
in each phase). The interval from sheath removal to 
reinstituting heparin infusion will be 6 hours in the 
first, 12 hours in the second, and 24 hours in the third 
phase. Whether the study should proceed as planned 
from one phase to the next will be decided on the basis 
of a predetermined incidence of acute or subacute 
thrombotic stent occlusion. If there are three or more 
incidences of subacute thrombosis in phase I where 
heparin is resumed 6 hours after sheath removal, the 
study will be stopped. This number is derived from 
the 3.8% subacute thrombosis rate in the Benestent I 
trial. If there are less than three occlusions, progression 
of the trial to phase I1 will take place (12 hours without 
heparin) and if less than three occlusions occur in 
phase 11, phase 111 will be entered where 24 hours 
will be allowed to relapse before restarting the heparin 
infusion. 
Coumadin (Du Pont Pharmaceuticals, Wilmington, 
DE, USA), acetyl salicylic acid (250-mg daily), dipyri- 
damol 75-mg tid, and diltiazem 120-nig bid, will be 
given as concomitant medication. Dextran will be 
given perioperatively and heparin will be administered 
according to the activated coagulation time. 
If the course of phase I11 is successful, i.e., there are 
less than three subacute thrombotic occlusions, further 
steps in the pilot phase will be considered. The hepa- 
rin-free interval may be prolonged to 48 hours or more, 
or the angiographic and clinical criteria may be wid- 
ened, e.g., allowing implantation in vessels < 3 mm 
and in patients with unstable angina pectoris. Of 
course, the data obtained for other study parameters 
will have to be taken into account at that time. There- 
fore, this extension of the trial has not been planned 
in detail. 
Summary and Conclusions 
It has been shown repeatedly in animal and clinical 
studies that heparin coating reduces thrombotic com- 
plications of several surfaces in contact with flowing 
blood. The demonstration that implantation of heparin- 
coated coronary stents is also effective in prevention 
of subacute thrombotic occlusion in a pig model offers 
the perspective of a clinical role of this treatment too. 
In order to put this to the test, the Benestent I1 pilot 
trial has been designed. This study will be conducted 
in a stepwise fashion in order to explore the feasibility 
of delaying deep anticoagulation as much as possible. 
Therefore, the primary goal is to minimize or exclude 
the need for heparin treatment following stent implan- 
tation. In addition, the effects on the need for revascu- 
larization procedures during follow-up will be 
recorded as well as the late morphological conse- 
quences as measured with quantitative coronary angi- 
ograph y . 
Appendix 
Benestent Study Group: Investigators and Co- 
Investigators. 
1. San Carlos, Madrid-C. Macaya, J .  Goicolea, 
F. Alfonso, A. Iniguez, Fernander, Herena, Diaz, R. 
Berdu. 
2. Thoraxcenter, Rotterdam-P.W. Serruys, P. de 
Jaegere, P. de Feyter, M. van den Brand, M-A. Morel. 
3. OLVG, Amsterdam-F. Kiemeneij, J-P. 
Smedema, H. Swart, G-J. Laarman, T. Slagboom, R. 
van der Wieken. 
4. Rudolf Virchov, Berlin-W. Rutsch. 
5 .  OLVZ, Aalst-G. Heyndrickx, B. de Bruyne, 
6. Sahlgrenska, Goteborg-H. Emanuelsson, P. 
7. Clinique Pasteur, Toulouse-J. Marco, J .  Faja- 
8. Sart Tilman, Likge-V. Legrand. 
9. La Citadelle, Li2ge-P. Materne, J. Boland. 
10. Instituto Cardiovascular, Buenos Aires-J. Be- 
1 I .  RBNHLB, London-U. Sigwart, N. Buller. 
12. Columbus Hospital, Milano-A. Columbo, L. 
13. CHUV, Lausanne-J. Goy, E. Eeckhout. 
14. Middelheim, Antwerp-P. van den Heuvel. F. 
1.5. Gregorio Maranon, Madrid-J. Delcan, L. 
16. De Weezenlanden, Zwolle-H. Suryapra- 
17. St. Antonius, Nieuwegein-T. Plokker, G. 
18. Ospitale Maggiore, Trieste-S. Klugmann, 
19. Kantonale, Geneva-P. Urban, E. Camenzind. 
P. Goemare, Nellens. 
Albertsson, L. Ekstrom, S.R. Johansson. 
det, S. Doucet, 0. Bar, Diaz, Jordan. 
lardi, R. Piraino, Berocal. 
Maiello. 
van den Branden. 
Garcia. 
nab,  J. Hoomtje. 
Mast, Suttorp. 
Della Grazia, A. Salvi. 
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20. Acad. Ziekenhuis, Groningen-P. den Heijer. 
21. AMC, Amsterdam-J. Piek, K.  Koch. 
22. Chris. Alb. University, Kiel-R. Simon, Herr- 
mann. 
23. CCN, St. Denis-M. Morice, T. Royer. 
24. St. James, Dublin-P. Crean. 
25. Catharina, Eindhoven-H. Bonnier, J.  
26. St. Luc. Brussels-W. Wijns, J .  Renkin. 
27. CHUR, Nancy-N. Danchin, Y. Yuillkre. 
28. Polyclinique Volney. Rennes-C. Bourdon- 
P. van Dijk. 
Koolen, F. Bracke. S. Roeffel, van Asperdt. 
nec. Descaves. 
Note: "Bold names" = minciual investigator. 
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